John Kastelein: Exploring the Biology of Cardiovascular Disease at BioCentury Grand Rounds Europe
John Kastelein, Co-Founder and Chief Scientific Officer at NewAmsterdam Pharma, Operating Partner of Forbion Capital Management, Chief Executive Officer of Vascular Research Network B.V., Co-Founder of Dezima Pharma and UniQure, shared a post on LinkedIn:
“I recently participated in BioCentury Inc. Grand Rounds Europe in Amsterdam, where I joined colleagues to discuss how advances in vascular biology, genetics, inflammation, thrombosis, and metabolism are changing the way we understand cardiovascular disease.
These mechanisms are deeply interconnected. Understanding why they work the way they do, and how we should scientifically approach them from different points of view, may help inform the next generation of cardiovascular therapies.
That is what makes discussions like this so valuable. Progress requires us to look beyond traditional boundaries, revisit longstanding assumptions, and remain open to where the research and the data lead.
I appreciated the opportunity to learn from my fellow panelists, Peter Carmeliet, Luca Andrea Lotta, and Pieter H. Reitsma, each of whom brought a valuable perspective to the conversation.
Thank you to BioCentury and to our moderator, Vanessa Carle, for bringing us together for such a thoughtful discussion.”

Stay updated with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines